Abstract
Low dose brachytherapy (LBT) is an accepted multidisciplinary curative treatment of localised prostate carcinoma. Biochemical response is monitored by measuring PSA value after implantation. When PSA rises, biochemical failure is feared, however an innocent PSA bounce is hoped for. We examined possible factors predicting a PSA bounce and also the relation to urological or gastrointestinal complications after LBT, neoadjuvant hormonal therapy (NHT) and physical and mental quality of life (QoL).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
